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Abstract
Multivalency of targeting ligands provides significantly increased binding strength towards their molecular targets. Here, we
report the development of a novel heptameric targeting system, with general applications, constructed by fusing a target-
binding domain with the heptamerization domain of the Archaeal RNA binding protein Sm1 through a flexible hinge
peptide. The previously reported affibody molecules against EGFR and HER2, ZEGFR and ZHER2, were used as target binding
moieties. The fusion molecules were highly expressed in E. coli as soluble proteins and efficiently self-assembled into
multimeric targeting ligands with the heptamer as the predominant form. We demonstrated that the heptameric molecules
were resistant to protease-mediated digestion or heat- and SDS-induced denaturation. Surface plasmon resonance (SPR)
analysis showed that both heptameric ZEGFR and ZHER2 ligands have a significantly enhanced binding strength to their target
receptors with a nearly 100 to 1000 fold increase relative to the monomeric ligands. Cellular binding assays showed that
heptameric ligands maintained their target-binding specificities similar to the monomeric forms towards their respective
receptor. The non-toxic property of each heptameric ligand was demonstrated by the cell proliferation assay. In general,, the
heptamerization strategy we describe here could be applied to the facile and efficient engineering of other protein domain-
or short peptide-based affinity molecules to acquire significantly improved target-binding strengths with potential
applications in the targeted delivery of various imaging or therapeutic agents..
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Introduction
Target binding affinity molecules are of great importance in
various biomedical applications. One of the major challenges in
developing targeting ligands is to improve their target-binding
strength while maintaining their high specificity. Although such
properties can be improved through extensive affinity maturation,
the process is slow, tedious, and often limited [1]. Currently, there
is an urgent need for the facile development of affinity molecules
that can bind to the targets of interest with high affinity and
specificity. One of the most critical design parameters for
satisfactory in vivo targeting is to increase targeting ligand valency,
defined as the number of antigen-binding sites [1]. Multivalent
targeting for the attainment of high binding affinity has known
natural examples, such as the binding between an antibody and its
target antigen: an intrinsic characteristic of mammalian antibod-
ies [1]. Multivalent targeting ligands maintain several major
advantages over monovalent ligands when targeting cell surface
receptors. First, the target-binding strength of the multivalent
ligand could be significantly improved [2]. Second, the multi-
merization process increases the molecular weight of the affinity
molecule above that of the glomerular filtration cut-off, thereby
reducing in vivo excretion while increasing tumor accumulation
characteristics via enhanced permeability and retention (EPR). For
example, it has demonstrated that monovalent binding is often not
sufficient for efficacious cancer targeting, and most monovalent
targeting ligands, despite nanomolar or picomolar binding
affinities, tend to have fast dissociation rates, providing modest
retention times on the target antigen in in vivo non-equilibrium
environments [1–3].
Due to these advantages, several techniques in multivalency
engineering of antibodies have been developed, including domain-
swapping, linear fusion, chemical linking, self-assembly, and
heterodimerization [1]. Most of these approaches are limited to
targeting ligands based on natural antibodies or their fragments.
However, a self-assembly approach based on the use of various
domains that permit self-multimerization may be a general
strategy for the systematic development of novel targeting ligands.
Recently, the self-assembly strategy has been successfully applied,
by exploring several multimerization domains, in generating
multivalent antibody fragments. These multimerization domains
includes TNF-alpha for the formation of homotrimers, the
amphipathic helix of GCN4, the multimerization peptide of p53
and the core domain of streptavidin for the formation of tetramers,
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and the coiled-coil assembly domain of cartilage oligomeric matrix
protein (COMP) and the B-subunit of bacterial verotoxin for the
formation of pentamers [4–11].
Successful and efficient conversion of a monovalent ligand into
a multivalent form is challenging and requires a combination of
unique features on both the target binding and the multi-
merization moieties. Due to the tendency of aggregation, steric
hindrance, and fast dissociation, only few self-multimerization
domains are suitable for efficient self-assembly [1]. First, the
scaffold should be small and soluble enough for high expression in
bacteria. Second, the self-assembly of a monomeric domain into its
multimeric form with desired valency should be very efficient with
extraordinarily high association constants and low aggregation
tendency. The resulting complex should have a well-defined
parallel multimeric structure with high stability that allows for the
introduction of target-binding moiety and hinge region to achieve
desired multivalency without disrupting target binding. This is
particularly challenging when the complex is significantly diluted
in the bloodstream under in vivo conditions. To circumvent these
problems, new multimerization domains require investigation for
the development of higher avidity targeting ligands.??
Targeting ligands with di-, tri-, tetra-, and pentavalency have
been developed, however, those with a valency higher than five
have not been reported and it is the focus of this study [4–14]. One
protein class featuring heptameric structures is the Sm or Sm-like
(Lsm) RNA-binding protein that has been implicated in a variety
of RNA processing events in all eukaryotic organisms [15].
Structural analyses indicate that the core domain of Sm protein
self-assembles into a heptameric complex with a doughnut-shaped
ring structure that accommodates uracil rich RNAs, as shown in
human canonical Sm core domain, human Lsm, and other Sm
proteins [15]. To generate novel heptameric targeting ligands with
high stability and binding affinity, we chose to use the 70-amino
acid multimerization domain from the hyperthermophilic Ar-
chaeal Sm protein. Recently, the crystal structures of the Sm1 and
Sm2 proteins from hyperthermophilic Archaeoglobus fulgidus (AF)
have been solved [16]. While the AF-Sm2 hexamer is RNA-
dependent and only stable at low pH, the AF-Sm1 heptamer is
highly stable regardless of pH and the absence of RNA.
Significantly, AF-Sm1 forms a seven-membered ring, presumably
due to the continuous inter-subunit hydrogen bonding between b-
strands 4 and 5. The thickness of the core ring is 32 Å, while the
outer and inner diameters are 65 Å and 13 Å, respectively [16].
In the present study, we have designed heptameric targeting
ligands towards EGFR or HER2 receptor by utilizing the
heptamerization domain of the AF-Sm1domain and EGFR- or
HER2-binding Z domain as the target binding moiety connected
through a flexible hinge peptide. The heptameric targeting ligands
Figure 1. Schematic diagram of monomeric and heptameric targeting ligands. (A) The cDNA of heptameric ligand consists of coding
regions for a target binding domain, a flexible hinge linker, and a heptamerization domain. A 66His-tag was introduced on the C-terminus of each
molecule. The structure of the monomeric targeting ligand is similar to the heptameric ligand with the exception of the absence of the
heptamerization domain. (B) Schematic representation of the monomeric and heptameric ligands;; Affibody (Z domain) structure was obtained from
PDB database (PDB ID:2B89).
doi:10.1371/journal.pone.0043077.g001
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were self-assembled with high efficiency, retained their binding
specificity, showed significantly enhanced target-binding strength,
and demonstrated unusually high stability with non-toxic property,
implying that this general heptamerization strategy has the
potential to be widely applied for the systematic improvement of
the target-binding strength of many affinity molecules, particularly
those based on small protein domains or short peptides.
Materials and Methods
Cell culture
EGFR-positive A431, EGFR-negative Jurkat, HER2-positive
SK-OV3, and HER2-low expressing MCF7 cells were obtained
from the UNC Tissue Culture Facility. All cell lines were
maintained by serial passage at 37uC in 5% CO2. A431 cells
were grown in DMEM, Jurkat cells in RPMI1640, SK-OV3 cells
in McCoy 5a, and MCF7 cells in MEM alpha media, respectively.
All media were supplemented with 10% fetal bovine serum,
100 units/mL of penicillin, and 0.1 mg/mL streptomycin.
Plasmid construction
The codon-optimized DNA sequences that code for the
heptamerization domain of the Archaeal SM1 gene, EGFR
(ZEGFR1907), and HER2 (ZHER2–342) targeting affibodies were
synthesized by GenScript (Piscataway, NJ). The design of each
monomeric and heptameric targeting ligand is shown in Figure 1.
The amino acid sequence for each component of the heptameric
targeting ligands is listed in Table 1. After PCR amplification, the
gene products containing the target binding domain, hinge linker,
and heptamerization domain, were digested with Nco I and Xho I.
The digested fragments were cloned into the corresponding sites
(Nco I and Xho I) of pET28b (Novagen, Darmstadt, Germany).
The cloned plasmids were confirmed by sequencing at UNC
sequencing facility prior to use in protein expression.
Protein expression and purification
Each expression vector was transformed into E. coli BL21 (DE3)
Rosseta cells (Novagen, Darmstadt, Germany). The positive clones
were selected on LB plates containing kanamycin (50 mg/mL) and
chloramphenicol (34 mg/mL). A single colony was selected and
grown in 5 mL of LB media overnight at 37uC. The resulting
culture was added to a flask with 500 mL of LB media containing
kanamycin (50 mg/mL) and chloramphenicol (34 mg/mL). The
cells were grown at 37uC until the optical density (at 600 nm)
reached 0.5 to 1.0. IPTG with a final concentration of 1 mM was
then added to the cell cultures, followed by incubation at 22uC for
16 h. After induction, the cells were spun down at 3,000 g for
10 min at 4uC, and the pellet was stored at 220uC until use. To
purify the monomeric and heptameric ligands, the cell pellet was
resuspended in buffer A (25 mM HEPES pH 7.4 and 300 mM
NaCl) and sonicated for 1 min for a total of 5 times. The soluble
fraction was recovered by centrifugation at 12,000 g for 10 min at
4uC. The resulting fraction was loaded onto a TALON metal
affinity column (Clontech, Mountainview, CA) pre-equilibrated
with buffer A. Approximately 20 column volumes of buffer A were
used for initial washing followed by extensive washing (20 column
Table 1. Amino acid sequences of each component of the heptameric targeting ligands.
Amino acids
ZEGFR MVDNKFNKEM WAAWEEIRNL PNLNGWQMTAFIASLVDDPS QSANLLAEAK KLNDAQAPK
ZHER2 MVDNKFNKEM RNAYWEIALL PNLNNQQKRAFIRSLYGDPS QSANLLAEAK KLNDAQAPK
Hinge Linker GPQPQPKPQPK PEPEPQPQGG
Heptamerization domain MPPRPLDVLN RSLKSPVIVR LKGGREFRGT LDGYDIHMNL VLLDAEEIQN GEVVRKVGSVVIRGDTVVFV SPAPGGE
doi:10.1371/journal.pone.0043077.t001
Figure 2. SDS-PAGE analysis of the purified monomeric and
heptameric targeting ligands. The purified heptameric ZEGFR,
monomeric ZEGFR, heptameric ZHER2, and monomeric ZHER2ligands were
separated on a 10% SDS-PAGE gel. About 5 mg of each protein was
applied to each lane.
doi:10.1371/journal.pone.0043077.g002
Figure 3. Native gel separation of monomeric and heptameric
targeting ligands. The purified monomeric ZEGFR, heptameric ZEGFR,
monomeric ZHER2 and heptameric ZHER2 ligands were separated on an
8% native gel. About 5 mg of the purified monomer or 20 mg heptamer
was loaded to the appropriate lane.
doi:10.1371/journal.pone.0043077.g003
EGFR or HER2 Targeting Heptameric Ligand
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volumes) with buffer B (buffer A with 20 mM imidazole). The
protein of interest was eluted with buffer C (buffer A with 200 mM
imidazole). The quality of the purified proteins was examined by
SDS-PAGE.
Native gel electrophoresis
An 8% discontinuous native gel was prepared without SDS and
reducing agents based on the standard Laemmli SDS-PAGE
protocol. About 5 mg of highly purified monomer or 20 mg
heptamer was loaded to the appropriate lane, and separated on an
8 % native gel. Proteins were stained with coomassie brilliant blue
R-250.
Analytical ultracentrifugation
Highly purified monomeric or heptameric ligands were
prepared in a buffer containing 25 mM HEPES pH 7.4 and
150 mM NaCl. The solution was centrifuged at 10,000 g for 20 h
at 20uC. The absorbance at 280 nm was recorded every 2 h
during centrifugation. Each resulting absorbance was fit into a self-
association model to calculate the molecular weight.
FlTC labeling of monomeric and heptameric targeting
ligands
Each monomeric and heptameric molecule was labeled with
fluorescein isothiocyanate (FITC) (ACROS organics, Geels,
Belgium) in 50 mM borate buffer (pH 8.5). Briefly, 1 mg of each
protein was reacted with a 25 molar excess of FITC in the reaction
buffer and incubated at room temperature for 2 h. The resulting
mixture was quenched by the addition of 100 mM Tris-HCl
(pH 8.8) at room temperature for 1 h. Un-reacted free FITC
molecules were removed by passing the reaction mixture through
a NAP-10 column (GE Healthcare, Piscataway, NJ). Extensive
dialysis was performed overnight using a 3 kDa molecular weight
cut off dialysis membrane (GE Healthcare, Piscataway, NJ) to
further remove the residual FITC.
Cell surface binding analysis
Approximately 26104 cells were seeded on coverslips and
allowed to grow in the appropriate media for 16 h. The resulting
coverslips were washed twice with 16PBS buffer followed by
incubation in different concentrations of FITC labeled monomeric
or heptameric targeting ligand for 30 min at room temperature.
The coverslips were washed three times with 16PBS. The
resulting samples were visualized by using Zeiss LSM 510 confocal
microscope at the UNC microscopy core facility.
Flow cytometry
Cell binding of the monomeric and heptameric ligands was
evaluated by using flow cytometry. Approximately 26105 cells per
sample were washed with PBS. Cells were incubated with FITC-
labeled monomeric or heptameric ligand for 30 min at room
temperature, followed by washing with PBS twice. The samples
were analyzed by flow cytometer (BD FACS Canto flow
cytometry) and the data were analyzed by Flow Jo system (Tree
star, Inc. Ashland, OR).
BIAcore analysis
The BIAcore 2000 (BIAcore AB, Uppsala, Sweden) was used
for surface plasmon resonance analysis. 1 mg of purified extracel-
lular domain of recombinant human EGFR ECD-Fc, HER2
ECD-Fc, or PSMA (R&D System, Minneapolis, MN), was diluted
in a buffer containing 10 mM sodium acetate pH 5.0 and
immobilized on CM5 sensor chip (GE healthcare, Piscataway,
NJ) by amine coupling according to the manufacturer’s instruction
(about 2,500 resonance units). Various concentrations of mono-
meric or heptameric ligands were injected onto the flow cell in an
HBS-P buffer (10 mM HEPES pH 7.4, 150 mM NaCl, and
0.005% surfactant P20) at a flow rate of 20 ml/min. The
dissociation equilibrium constant (KD), the association rate (Ka),
the dissociation rate (Kd) were calculated using the BIAevaluation
software (BIAcore) by fitting the data on a one to one Langmuir
binding model.
Circular dichroism spectroscopy
Highly purified monomeric or heptameric proteins were
prepared in 10 mM phosphate buffer (pH 7.5) and used for
circular dichroism (CD) scanning with an AVIV model 202-01
spectropolarimeter at the UNC macromolecular interaction
facility. Spectra were recorded from 190 nm to 260 nm at
0.2 nm intervals, a scan speed of 20 nm/min, a bandwidth of
2 nm, and an integration time of 1 s. To determine thermal
stability, spectra were recorded by gradually increasing the
temperature from 25uC to 94uC at 220 nm.
Figure 4. Determination of the molecular weights of the heptameric targeting ligands by analytical ultracentrifugation analysis.
Purified heptameric ZEGFR and heptameric ZHER2 ligands were centrifuged at 10,000 g for 20 h. Absorbances at 280 nm were recorded every two
hours.
doi:10.1371/journal.pone.0043077.g004
EGFR or HER2 Targeting Heptameric Ligand
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Resistance to protease-mediated degradation
The protease digestion was performed in HBS buffer (10 mM
HEPES pH 7.4 and 150 mM NaCl) at 25uC, 37uC, 42uC, and
60uC, respectively, for 20 min. About 5 mg of each protein was
incubated with 100 ng of thermolysin. After incubation, the
resulting reaction mixtures were separated by SDS-PAGE to
monitor the extent of protein degradation.
Co-localization studies
A431 and SK-OV3 cells were seeded onto the coverslips and
grown for 16 h at 37uC. FITC-labeled 10 nM or 100 nM of
heptameric ZEGFR and ZHER2 were incubated for 2 h at 37uC with
A431 and SK-OV3 cells grown on coverslips, respectively. After
washing away unbound targeting ligands, the cells were fixed with
2% paraformaldehyde in PBS for 15 min at room temperature.
Cells were then washed three times with 16PBS. For immuno-
staining, blocking solution (PBS with 5% BSA and 0.3% Triton X-
100) was added and incubated for 1 h at 4uC. The cells were then
incubated with the anti-EEA1 rabbit monoclonal antibody (1:200)
(Cell Signaling Technology, Danvers, MA) overnight at 4uC. After
incubation with secondary antibody (Alexa Fluor 555 conjugated
anti-Rabbit IgG (Cell Signaling Technology, Danvers, MA) for
Figure 5. Heat stability assessment of the monomer and the heptamer by circular dichroism analysis. (A) Monomeric and heptameric
ZEGFR, (B) monomeric and heptameric ZHER2 targeting ligands, and (C) heptameric core itself were prepared in a 10 mM phosphate buffer, pH 7.4.
Temperature was increased from 25uC to 94uC. Spectra were recorded at various temperatures. The ellipticity at 220 nm was used for the analysis.
doi:10.1371/journal.pone.0043077.g005
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1 h at 4uC, the corresponding cells were rinsed three times with
16PBS followed by the addition of an antifade reagent. Cells were
examined by using Zeiss LSM 510 confocal microscope at the
UNC microscopy core facility.
Cell proliferation MTS assay
CellTiter96 Aqueous Non-Radioactive Cell Proliferation Assay
kit from Promega (Madision, WI) was used for the MTS assay.
Approximately 16104 cells were seeded in each well of a 96-well
plate and grown for 16 h at 37uC. Each heptameric molecule was
incubated with the cells for 24 h. 4 mM Cis-platinum (II) diamine
dichloride (Sigma-Aldrich Chemical Co, St Louis, MO) was used
as a positive control. Approximately 20 ml of MTS/PMS solution
was added into each well followed by incubation for 4 h at 37uC.
The absorbance at 490 nm was recorded using an ELISA plate
reader.
Results
General design of heptameric targeting ligands
In the previous self-association approaches for the generation of
trimeric and pentameric complexes, additional cysteine (Cys)
residues were introduced to stabilize the oligomeric structure
through the formation of inter-molecular disulfide bonds
[10,11,14,17]. However, the formation of undesired disulfide
bonds is common, resulting in mis-folding, aggregation, and loss of
target-binding functions [1]. To circumvent these problems, we
decided to use the 70-amino acid AF-Sm1 heptamerization
domain from hyperthermophilic Archaeoglobus fulgidus, which is
highly stable and can efficiently self-assemble into a parallel
heptameric complex without relying on any disulfide
bond(Figure 1).
The general strategy we used to develop the heptameric
targeting ligands is to fuse a small target-binding protein domain
through a hinge linker with the AF-Sm1 heptamerization domain
(Figure 1A). To investigate whether functional heptameric
Figure 6. Analysis of the protease resistance of the monomer and the heptamer by thermolysin. (A) About 5 mg of monomeric and
heptameric ZEGFR and (B) monomeric and heptameric ZHER2 targeting ligands were incubated with 100 ng of thermolysin at different temperatures
for 20 min. After incubation, reaction was stopped by adding SDS sample buffer and each reaction mixture was separated on a 10% SDS-PAGE to
examine protein degradation.
doi:10.1371/journal.pone.0043077.g006
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targeting ligands can be readily generated using this strategy, we
used an EGFR- or HER2-binding affibody, ZEGFR or ZHER2, that
does not contain any Cys residue, as reported in the literature, to
facilitate the self-assembly process [18,19]. The affibody is
composed of 58-amino acid derived from the immunoglobulin
binding Z-domain of staphylococcal protein A [18], a small (,7 kDa)
protein domain with a three-helix bundle structure (Figure 1B). It
has been extensively reported that the affibody could be selected
with high affinity to any given target from a library with high
diversity [18,19]. To compare the monomeric and the corre-
sponding heptameric forms, the monomeric targeting ligands were
constructed by deleting the heptamerization domain (Figure 1A).
In addition, a His-tag was introduced at the C-terminus of both
monomeric and heptameric ligands to facilitate protein purifica-
tion.
Expression, purification and characterization of
monomeric and heptameric targeting ligands
The cDNAs that encode the monomeric and heptameric
targeting ligands were cloned into a pET28b expression vector
that contains a C-terminal 66His-tag to facilitate protein
purification by Co2+-nitrilotriacetic acid (NTA) column. The
expression level of the targeting ligands was high with a yield of
approximately 20 mg/L and 10 mg/L for the monomeric and
heptameric ligands as soluble proteins, respectively. Co2+-NTA
purified monomeric and heptameric ligands were analyzed by
SDS-PAGE (Figure 2). The predicted molecular weight of the
monomeric targeting ligands without the heptamerization domain
is about 10.2 kDa for ZEGFR and 10.5 kDa for ZHER2, respec-
tively. In the case of heptameric ligands, the monomeric form with
the AF-Sm1 domain has a molecular weight of 18 kDa, whereas
its corresponding heptameric form has a predicted molecular
weight of 126 kDa. As shown in Figure 2, both monomeric ZEGFR
and ZHER2 could be purified to near homogeneity. When a
heptamerization domain was introduced in the construct, the vast
majority of the expressed protein was present in a multimeric form
with molecular weight of approximately 130 kDa, even though a
small portion of the monomeric form (18 kDa) was also detected
(Figure 2). Because the molecular weight of the multimeric form
(130 kDa) is very close to that of the putative heptameric form
(126 kDa), it strongly suggests that this multimeric form is the
putative heptamer. It appears that the formation of the heptameric
form was efficient without applying any special folding procedures,
as shown by SDS-PAGE (Figure 2). The heptameric form is highly
stable since it can resist the strong denaturing conditions of SDS
present in the loading buffer as well as in the polyacrylamide gel.
This result clearly indicates that the self-assembly to a heptameric
form is robust and highly efficient. The presence of a small amount
of the monomeric form on SDS-PAGE raises question whether the
monomeric form co-exists with the heptameric form before SDS-
PAGE analysis or it is generated by disassembling the heptameric
form back to the monomeric form when denaturing conditions
were applied during SDS-PAGE. To address this question, we
further examined the purified heptameric ligands by using native
gel electrophoresis. As shown in Figure 3, both purified
heptameric ZEGFR and ZHER2 targeting ligands were present as
a single band under non-denaturing conditions with much lower
mobility compared with monomeric ligands, whereas the corre-
sponding 18 kDa monomeric form was not detected. Taken
Figure 7. Binding dynamics of monomeric and heptameric targeting ligands by BIAcore analysis. The extracellular domain of (A) EGFR
and (B) HER2 receptors were immobilized on the CM5 chip. Different concentrations of monomer or heptamer proteins were injected into the
channels. Analyses were performed at room temperature at a flow rate of 20 ml/min.
doi:10.1371/journal.pone.0043077.g007
Table 2. Binding constants of each monomeric and
heptameric targeting ligand using BIAcore analysis.
Ka (1/Ms) Kd (1/s) KD (M)
ZEGFR monomer 6.076104 1.5961024 2.6261029
ZEGFR heptamer 1.916104 5.6761027 2.9610211
ZHER2 monomer 1.696105 2.9561024 1.7561029
ZHER2 heptamer 3.156104 7.1561028 2.27610212
doi:10.1371/journal.pone.0043077.t002
EGFR or HER2 Targeting Heptameric Ligand
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together, the self-assembled multimeric targeting ligands exist
predominately as a heptameric form under native conditions.
Although the molecular weight of the heptameric form on SDS-
PAGE is around 130 kDa, it is of great interest to measure the
exact molecular weight of the putative heptamer. To further
confirm the heptameric state, we used analytical ultracentrifuga-
tion to determine the molecular weights of both heptameric
ligands. As shown in Figure 4, the two putative heptameric
targeting ligands have a molecular weight of 13163 kDa for
heptameric ZEGFR and 13062 kDa for heptameric ZHER2,
respectively. These values are consistent with those shown from
SDS-PAGE gels and also match the theoretical molecular weights
(,126 kDa) of the heptameric form. Altogether, we concluded
that the multimerization domain containing targeting ligand can
self-assemble into a heptameric form very efficiently under native
conditions while the presence of the monomeric form is minimal.
An ideal affinity molecule should have exceptional stability to be
readily used in various in vitro and in vivo applications. To
determine the thermal stability of these targeting ligands, we
performed circular dichroism (CD) analysis using highly purified
monomeric and heptameric proteins. Thermal denaturation was
monitored at 220 nm. As shown in Figures 5A and 5B, the Tm
value of each protein is approximately 65uC for all ligands,
whereas the heptameric complex itself is highly resistant to heat-
induced denaturation (Figure 5C). These results indicate that
heptameric ZEGFR and ZHER2 ligands are as stable as monomeric
ligands. Degradation of protein-based affinity molecules by various
physiological proteases is another barrier that must be overcome
for their in vivo applications. To examine the resistance of these
targeting ligands to proteases, we performed a protease-mediated
digestion assay by subjecting the monomeric or heptameric
targeting ligands to a thermostable metallopeptidase thermolysin
according to the procedure we have reported [20]. All of the
heptameric forms were resistant to thermolysin digestion even
when the temperature was as high as 60uC, whereas monomeric
forms are more susceptible to protease at 60uC(Figures 6A and
6B). This result demonstrates that such heptameric targeting
ligands are stable under harsh conditions, implying that they have
a higher potential of being resistant to degradation in vivo and used
as targeting ligands for in vivo applications.
The determination of target binding strength
To investigate whether purified heptameric complex main-
tained the target binding features towards the target of interest,
surface plasmon resonance (SPR) was employed to examine the
binding strength and specificity of the monomeric and heptameric
ligands. Here, we immobilized the extracellular domains of EGFR
or HER2 on the surface of CM5 biosensor chip followed by
injection of purified monomeric or heptameric ligands. No binding
was detected for any of the targeting ligands when an irrelevant
protein target, such as PSMA (Prostate Specific Membrane
Antigen), was used as a negative control (data not shown). As
expected, it was evident that ZEGFR targeting ligands did not bind
to HER2 receptor, and neither ZHER2 targeting ligands showed
any detectable binding against EGFR (data not shown). The
binding constant KD of the monomeric Z
EGFR ligand
(2.660.3 nM) by fitting data on one to one Langmuir binding
model was similar to that of affibody (5 nM) reported by Stahl and
co-workers (Table 2 and figure 7A) [19]. The heptameric ZEGFR
ligand has greatly enhanced EGFR-binding strength at KD of
29620 pM, which is approximately 100 fold higher than that of
the monomeric form (Table 2). In the case of the heptameric
ZHER2 ligand, about 1000 fold increased HER2-binding strength
(KD of 2 60.5 pM) was achieved compared to that of the
monomeric ZHER2 ligand (KD of 1.760.7 nM) (Table 2 and
Figure 7B). These results clearly indicate that the target binding
strengths of heptameric ligands have significantly increased as a
result of the multivalency effect.
Binding of monomeric and heptameric targeting ligands
with cell surface biomarkers
The multivalent binding effect of heptameric ligands depends
on many factors, particularly the density of target receptors on the
cell surface. The density of each target receptor on CM5 chip is
quite different from that on the surface of live cells. Although we
used purified proteins originated from mammalian cells to
circumvent post-translational modification issues, the SPR exper-
Figure 8. Cell-based surface receptor binding properties of the
monomer and heptamer. (A) EGFR-positive A431 cells were grown
on coverslips. Different concentration of FITC-labeled monomeric and
heptameric ZEGFR ligands was incubated with A431 cells for 30 min at
25uC. (B) HER2-positive SK-OV3 cells were grown on coverslips. FITC-
labeled monomeric and heptameric ZHER2 ligands were incubated with
SK-OV3 cells for 30 min at 25uC. (C) EGFR-negative Jurkat cells and
HER2-low expressing MCF7 cells were grown on coverslips. 100 nM of
FITC-labeled monomeric and heptameric ligands were incubated with
Jurkat and MCF cells for 30 min at 25uC.
doi:10.1371/journal.pone.0043077.g008
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imental conditions cannot mimic the in vivo cellular conditions and
therefore this warranted further investigation of the heptameric
ligands through cell surface binding assays. To investigate the
target-binding properties of each ligand using cell lines that
overexpress native EGFR or HER2, we labeled each targeting
ligand with FITC to visualize its binding with cells. For
monomeric and heptameric ZEGFR ligands, we used A431 cells
that overexpress EGFR, while EGFR-negative Jurkat cells were
used as a negative control. The binding signal can be easily
detected on EGFR-expressing A431 cells when both monomeric
and heptameric ZEGFR ligands were used (Figure 8A). In contrast,
minimal fluorescent signal was observed on Jurkat cells when
either monomeric or heptameric ZEGFR ligand was used, even
when the concentration of the targeting ligand was as high as
100 nM (Figure 8C). The cell binding strength of heptameric
ZEGFR ligand is much stronger than that of the monomeric ligand.
As shown in Figure 8A, 10 nM of monomeric ZEGFR ligand was
required to achieve the same cell binding signal compared to
0.1 nM of heptameric ZEGFR ligand. We also compared the cell-
binding properties of the monomeric and heptameric ZHER2
targeting ligands by using SK-OV3 cells that highly express
HER2, while MCF7 cells with a much lower HER2 expression
level were used as a negative control. As shown in Figure 8B, as
low as 0.1 nM heptameric ZHER2 ligand bound to HER2-positive
SK-OV3 cells, whereas more than 10 nM monomeric ZHER2
ligand was required to achieve comparable results (Figure 8B).
However, no detectable binding to MCF cells was observed even
when 100 nM of monomeric or heptameric ligand was used
Figure 9. Cell binding analysis by flow cytometry. (A) 100 nM FITC-monomeric and heptameric ZEGFR ligands were used for labeling of EGFR
positive A431 and negative Jurkat cells, and analyzed by flow cytometry. Cells incubated with PBS were served as negative control. (B) 100 nM FITC-
monomeric and heptameric ZHER2 ligands were used for labeling of HER2 positive SK-OV3 and HER2 low expressing MCF7 cells, and analyzed by flow
cytometry. Cells incubated with PBS were served as negative control.
doi:10.1371/journal.pone.0043077.g009
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(Figure 8C). These results were consistent with the SPR data that
both monomeric and heptameric ZHER2 ligands bound HER2
receptor specifically. Taken together, these observations indicate
that heptameric targeting ligands can specifically bind to their cell
surface biomarkers and their binding strengths are at least 100 fold
higher than the monomeric ligand. Additionally, we have
conducted cell binding analysis by using flow cytometry. The
100 nM FITC-labeled monomeric and heptameric ZEGFR ligands
were incubated with A431 and Jurkat cells, respectively. No
binding was detected on EGFR negative Jurkat cells (Figure 9A).
However, strong binding signal was detected on EGFR positive
A431 cells by using both monomeric and heptameric ligand
(Figure 9A). Heptameric ZEGFR ligand bound to A431 cells about
10 fold stronger than monomeric ZEGFR ligand (Figure 9A).
Similarly, the 100 nM FITC- labeled monomeric and heptameric
ZHER2 ligands were incubated with SK-OV3 and MCF7 cells,
respectively. Both monomeric and heptameric ligands bound to
SK-OV3 strongly and maintained target receptor binding
specificity even though the heptameric ZHER2 ligand bound to
MCF7 weakly (Figure 9B). It was also confirmed that heptameric
ZHER2 bound to SK-OV3 cells stronger than monomeric ZHER2
(Figure 9B). According to flow cytometry analysis, both hepta-
meric ligands bound stronger to their target receptor compared to
the corresponding monomeric ligands. It is possible the weak
binding of heptameric ZHER2 ligand to MCF7 cells, which express
low level of HER 2, is due to the avidity effect of the heptameric
ligand. Collectively, target binding specificity of each heptameric
ligand was well maintained along with strong binding affinity.
Heptameric targeting ligands are internalized and
present in the endosome
One of exciting applications of targeting ligands is the delivery
of imaging or therapeutic agents into specific cell types. Therefore,
it is important to study whether targeting ligands can be
internalized and to further investigate the sub-cellular localization
of the internalized molecules. It is well known that the binding of
EGF to EGFR promotes the internalization of the receptor
through the endocytic pathway, and the internalized EGFR is
strongly associated with an early endosome marker Early
Figure 10. Co-localization of EEA1 and heptameric targeting
ligands. (A) Two different concentrations of the FITC-labeled
heptameric ZEGFR targeting ligands were incubated with A431 cells
for 2 h at 37uC. (B) FITC labeled heptameric ZHER2 targeting ligands at
two concentrations were incubated with SK-OV3 cells for 2 h at 37uC.
EEA1 proteins were detected by Alexa 555-conjugated secondary
antibody. Top left panels: cell nuclei stained with DAPI (blue); Top right
panels: FITC labeled heptamer (green); bottom left panels: EEA1
antibody (red); bottom right panels: merged image of the three
stainings.
doi:10.1371/journal.pone.0043077.g010
Figure 11. Analysis of cellular toxicity of heptameric targeting
ligands by the MTS assay. A431 and SK-OV3 cells were incubated
with various concentrations from 250 nM to 4 mM of each heptameric
targeting ligand for 24 h at 37uC. Cisplatin (4 mM) was used as a positive
control. Cells without the targeting ligands or without cisplatin were
used as a negative control. Absorbance at 490 nm (A490) was
measured.
doi:10.1371/journal.pone.0043077.g011
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Endosome Antigen 1(EEA1) that is enriched in endosomes [21].
The monomeric and heptameric ZEGFR ligands used in this study
contain the same affibody (Z1907) as reported in the literature
[22]. Recently, it was reported by Frejd and co-workers that
monomeric and dimeric EGFR-binding affibody (Z1907) were
internalized as efficiently as EGFR monoclonal antibody cetux-
imab when they were incubated with A431 cells [22,23].
To investigate the internalization and subsequent sub-cellular
location of heptameric ZEGFR ligand, the targeting ligand was
incubated with A431 cells at 37uC for 2 h to promote its
internalization. As illustrated in Figure 10A, bright punctuated
dots can be observed using confocal microscopy, demonstrating
that FITC labeled heptameric ZEGFR (green fluorescence) was
internalized and co-localized (white arrows) with the early
endosome marker EEA1 (red fluorescence). However, some of
the heptameric ligand signal (green) did not overlap with EEA1
(red). It is possible that some of heptameric ligands might escape
from endosome or localize within late endosome that cannot be
detected through EEA1. Similarly, the sub-cellular localization of
heptameric ZHER2 ligand was also investigated by incubating
FITC labeled heptameric ZHER2 ligands with SK-OV3 cells. It
appears that heptameric ZHER2 ligand also co-localized with
EEA1 in endosomes (Figure 10B), but more heptameric ZHER2
ligands are present on cell surface when compared to the
heptameric ZEGFR ligand. Our results are consistent with previous
finding that HER2 endocytosis and HER2 mediated uptake of
affibody were slower than that of EGFR [24,25]. These findings
clearly demonstrated that both heptameric targeting ligands were
internalized and co-localized with EEA1in endosome.
Cellular toxicity of the heptameric targeting ligands
The internalization property of the heptameric ligands may be
used for the intracellular delivery of a variety of agents such as
anti-cancer drugs and imaging agents. However, an ideal targeting
ligand must have minimal cellular toxicity. To examine the degree
of cellular toxicity of the heptameric ligands, their effect on cell
proliferation was assessed by the MTS assay. Various concentra-
tions ranging from 250 nM to 4 mM of an appropriate heptameric
ligand was incubated with EGFR-positive A431 or HER2-positive
SK-OV3 cells. The anti-cancer drug cisplatin that interferes with
cancer cell growth by inhibiting DNA metabolism through its
binding to DNA was used as a positive control [26]. Figure 11
illustrates that heptameric ligands showed very little cell growth
inhibition (at most 4%), while cisplatin at 4 mM inhibited cell
proliferation to 50%. These results indicate that the heptameric
targeting ligands by themselves are not toxic to cells at least under
the conditions we have investigated (at concentrations up to
4 mM).
Discussion
The role of multivalency in enhancing affinity of a ligand
towards its target has been well studied [1]. The ideal targeting
ligand with desired multivalency should be composed of multiple
target-binding moieties displayed in parallel surrounding a multi-
meric core with unusually high stability. However, the generation
of novel multivalent targeting ligands with desired properties, such
as high stability and significantly improved functional affinity, is a
difficult task. Here, we report the first successful generation of
heptameric targeting ligands, against EGFR and HER2 receptor,
using the heptamerization domain from the Archaeal RNA
binding protein (Figures 1A and 1B). On the basis of our findings,
it appears that the AF-Sm1 domain has several unique advantages
to serve as an ideal scaffold for heptamerization of targeting
ligands. These features include its cysteine-free amino acid
sequence, spontaneous and highly efficient self-assembly process,
exceptionally high stability against heat and protease-induced
degradation, economical and high expression level in E. coli, and
non-existing cellular toxicity.
In addition to a robust heptameric core, it is necessary to have
an affinity moiety and a flexible linker to make a functional
heptameric targeting ligand possible. We decided to use previously
well-characterized, widely used EGFR- and HER2-binding
affibodies (,7 kDa) as the affinity molecules [18,19]. These
affibodies were previously selected by phage display that bound
the extracellular domain of EGFR or HER2 with sub-nanomolar
affinities [18,19]. Unlike display of short peptides with just a few
amino acids, display of seven protein domains at the top of a
heptameric core without affecting the right geometry is challeng-
ing. The AF-Sm1 domain-based heptameric core is very compact
and rigid, with the outer and inner diameters of 65 Å and 13 Å,
respectively [16]. To facilitate the parallel display of seven AF-
Sm1 domains, we introduced a flexible hinge linker between the
target binding moiety and the heptamerization domain, which
presumably provides greater inter-unit spacing so that each
monomeric ZEGFR or ZHER2 can be properly folded without
disrupting the heptameric complex. Since multiple affinity units
are present to the targets on cell membrane at a very close
distance, the free energy of target binding with the heptameric
ligand should be much higher than that with the monomeric
ligand. Indeed, significantly improved target-binding strength of
the heptameric ligands was observed when compared to the
respective monomeric ligands (Figure 7 and Table 2).
Both heptameric ZEGFR and ZHER2 ligands were highly stable as
demonstrated by its efficient formation even under harsh
denaturing conditions, such as SDS- or heat-induced denaturation
(Figures 2, 5 and 6). No detectable monomeric ligand was
observed under native conditions (Figure 3), suggesting that the
small amount of monomeric form observed in the SDS-PAGE gels
is likely due to the dissociation of a small proportion of the
heptamer under denaturing conditions (Figure 2). Moreover, the
high stability of heptameric ligands was demonstrated by CD
analysis and protease-mediate degradation (Figure 5 and 6). Both
heptameric ligands were as stable as their monomeric counterparts
as the temperature was raised to 94uC during CD analysis
(Figures 5A and 5B). The minimal degradation by thermolysin, a
highly active protease at high temperature, provided further
evidence that the heptameric ligands have exceptional high
stability (Figures 6A and 6B). The Archaeal derived heptameriza-
tion domain has been evolutionarily selected to withstand extreme
environmental conditions such as high temperature and low pH
[15]. The exceptional high stability of AF-Sm1 can be well-
explained by examining its X-ray crystal structure, in which the
doughnut shaped heptameric ring is extensively stabilized by the
inter-subunit b sheet hydrogen bonding and the combination of
hydrophobic and electrostatic interactions at the interface of each
monomeric subunit [16]. Each heptameric ligand maintains its
target-binding specificity without cross reactivity (Figures 7A and
7B; and Table 2). The in vitro target-binding strength of the
heptameric ligands was significantly enhanced (up to 1000 fold)
compared to the monomeric ligands as shown by SPR studies
(Figure 7 and Table 2). This is presumably due to the greatly
reduced dissociation rate, which is slowed down 280 and 4,000
times in heptameric ZEGFR and ZHER2, respectively (Table 2).
However, cell binding analysis indicated that heptameric ligands
showed only 100 fold increase in binding with EGFR- or HER2-
positive cells (Figure 8). The discrepancy of binding strength
between in vitro and in vivo analyses is typical as observed in many
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other targeting ligands. First, the density and the accessibility of a
receptor on the cell surface are quite different from that on the
CM5 chip. The presence of various other receptors and proteins
on the cell membrane should result in limited accessibility of the
cell surface receptor by its ligand. Another possibility for the
marginal difference between monomeric and heptameric ligands
in cellular studies is that the affinity of the monomers we used is
already in the range of low nanomolars, making it difficult to
further increase through multivalency [27]. Furthermore, the
covalent labeling of targeting ligands with FITC for in vivo cellular
studies may lead to the modification of some residues that are
critical for targeting binding, consistent with the report by
Lyakhovin the studies of interaction between EGFR-binding
affibody and its receptor [28].
The receptor-bound heptameric ligands were efficiently inter-
nalized and further co-localized with the early endosome marker
EEA1. This finding indicates that the heptameric system can be
utilized as a carrier for intracellular delivery of various anticancer
agents. Indeed, we have demonstrated recently that nickel
nanoparticles (Ni-NP) conjugated with heptameric ZEGFR ligand
can be used for efficient targeting EGFR-positive A431 cells, with
more than 9-fold increase of cellular uptake compared to
untargeted nanoparticles [29]. Furthermore, the heptameric
ZEGFR ligand could facilitate in vivo accumulation of Ni-NPs in
nude mice bearing A431 cells [29]. These results support our
hypothesis that the heptameric targeting system described here has
the great potential to be widely used for various in vivo applications.
Compared with our previous pentameric targeting ligand, it
appears that the heptameric ligands do not increase the target-
binding strength to more than 104 [20]. However, it is difficult to
directly compare these systems since different scaffolds of the
targeting moieties were used. Nevertheless, the heptameric system
has several unique advantages. First, the heptameric targeting
ligand exists predominantly as a heptamer without any detectable
intermediate forms. This is very different from the pentameric
ligand that is present as a mixture of tri-, tetra-, and pentameric
forms that complicate the purification process [20]. Second, the
spontaneous and highly efficient self-assembly of the heptameric
ligand is totally independent on the disulfide bond(s), but relies on
the extensive inter-subunit hydrogen bonding, hydrophobic and
electrostatic interactions. In contrast, the pentameric complexes
rely on the critical inter-subunit disulfide bonds to maintain its
multimeric structure. Third, the cysteine-free nature of the
heptameric ligand can greatly facilitate its site-specific conjugation
with other biomolecules, such as anticancer agents or nanopar-
ticles, by introduction of the only cysteine at the N- or C-terminus.
The facile and economic generation of these high-avidity affinity
molecules makes them a valuable complement to the conventional
antibody-based targeting ligands for both in vitro and in vivo
applications. One additional advantage of the heptameric system is
the spontaneous increase of the molecular weight from 18 kDa in
monomer to greater than 130 kDa in heptamer, which could
presumably extend the in vivo half-life of these ligands by reducing
kidney clearance.
In summary, our results demonstrate that heptameric targeting
ligands with high stability, enhanced avidity, and non-toxicity can
be easily generated through a facile and highly efficient self-
assembly process. Although the heptameric targeting ligands we
demonstrated here are for binding with EGFR or HER2
receptors, the same approach should be generally applied to the
rapid generation of high-avidity affinity molecules based on other
target-binding moieties such as short homing peptides, single
domain antibody mimics, and natural antibody fragments. Our
current and future work will explore the application of these
heptameric molecules for the targeted delivery of anticancer
agents. It is worth mentioning that the AF-Sm1 domain is a robust
RNA-binding complex [15], making it possible to use the
heptameric ligands described here for the targeted delivery of
nucleic acid drugs simply by add-and-mix strategy.
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